A Phase 1 Study of MOR209/ES414 in Patients Wtih Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Phase 1 Study of MOR209/ES414 in Patients Wtih Metastatic Castration-Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs MOR209-ES414 (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Aptevo Therapeutics; Emergent Product Development Seattle
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 Mar 2017 According to an Aptevo Therapeutics media release, company has initiated protocol amendment in this trial to add continuous infusion of MOR209/ES414.
    • 08 Sep 2015 According to MorphoSys media release, final clinical data expected in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top